




### Claim Amendments

(previously presented). A compound of Formula (I)



(I)

wherein


A is an optionally substituted aryl or an optionally substituted heteroaryl;

B is an optionally substituted aryl or an optionally substituted heteroaryl;


R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, or (C<sub>1</sub>-C<sub>4</sub>)alkoxy;

R<sup>4</sup> is

(i) a group having Formula (IA) or Formula (IB)



(IA)



(IB)

where R<sup>4a</sup> is hydrogen or (C<sub>1</sub>-C<sub>3</sub>)alkyl;

R<sup>4b</sup> and R<sup>4b'</sup> are each independently hydrogen, cyano, hydroxy, amino, H<sub>2</sub>NC(O)-, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>amino-, (C<sub>3</sub>-C<sub>6</sub>)cycloalkylamino-, acylamino-, aryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or either R<sup>4b</sup> or R<sup>4b'</sup> taken together with R<sup>4e</sup>, R<sup>4e'</sup>, R<sup>4f</sup>, or R<sup>4f'</sup> forms a bond, a methylene bridge, or an ethylene bridge;

X is a bond,  $-\text{CH}_2\text{CH}_2-$ , or  $-\text{C}(\text{R}^{4c})(\text{R}^{4c'})-$ , where  $\text{R}^{4c}$  and  $\text{R}^{4c'}$  are each independently hydrogen, cyano, hydroxy, amino,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , acyloxy, acyl,  $(\text{C}_1-\text{C}_3)\text{alkyl-O-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl-NH-C}(\text{O})-$ ,  $((\text{C}_1-\text{C}_4)\text{alkyl})_2\text{N-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_6)\text{alkylamino-}$ ,  $\text{di}(\text{C}_1-\text{C}_4)\text{alkylamino-}$ ,  $(\text{C}_3-\text{C}_6)\text{cycloalkylamino-}$ , acylamino-, aryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , heteroaryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or either  $\text{R}^{4c}$  or  $\text{R}^{4c'}$  taken together with  $\text{R}^{4e}$ ,  $\text{R}^{4e'}$ ,  $\text{R}^{4f}$ , or  $\text{R}^{4f'}$  forms a bond, a methylene bridge or an ethylene bridge;

Y is oxygen, sulfur,  $-\text{C}(\text{O})-$ ,  $-\text{C}(=\text{N-OH})-$ , or  $-\text{C}(\text{R}^{4d})(\text{R}^{4d'})-$ , where  $\text{R}^{4d}$  and  $\text{R}^{4d'}$  are each independently hydrogen, cyano, hydroxy, amino,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , acyloxy, acyl,  $(\text{C}_1-\text{C}_3)\text{alkyl-O-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl-NH-C}(\text{O})-$ ,  $((\text{C}_1-\text{C}_4)\text{alkyl})_2\text{N-C}(\text{O})-$ ,  $\text{HO-NH-}$ ,  $(\text{C}_1-\text{C}_6)\text{alkylamino-}$ ,  $\text{di}(\text{C}_1-\text{C}_4)\text{alkylamino-}$ ,  $(\text{C}_3-\text{C}_6)\text{cycloalkylamino-}$ , acylamino-, aryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , heteroaryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $\text{R}^{4d}$  and  $\text{R}^{4d'}$  taken together form a partially or fully saturated, 3- to 6-membered heterocyclic ring, a 5- or 6-membered lactone ring, or a 4- to 6-membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, or

Y is  $-\text{NR}^{4d''}-$ , where  $\text{R}^{4d''}$  is a hydrogen or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_3-\text{C}_6)\text{cycloalkyl}$ ,  $(\text{C}_1-\text{C}_3)\text{alkylsulfonyl-}$ ,  $(\text{C}_1-\text{C}_3)\text{alkylaminosulfonyl-}$ ,  $\text{di}(\text{C}_1-\text{C}_3)\text{alkylaminosulfonyl-}$ , acyl,  $(\text{C}_1-\text{C}_6)\text{alkyl-O-C}(\text{O})-$ , aryl, and heteroaryl, where said chemical moiety is optionally substituted;

Z is a bond,  $-\text{CH}_2\text{CH}_2-$ , or  $-\text{C}(\text{R}^{4e})(\text{R}^{4e'})-$ , where  $\text{R}^{4e}$  and  $\text{R}^{4e'}$  are each independently hydrogen, cyano, hydroxy, amino,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety

selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, di(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, (C<sub>3</sub>-C<sub>6</sub>)cycloalkylamino-, acylamino-, aryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,


or either R<sup>4e</sup> or R<sup>4e'</sup> taken together with R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, or R<sup>4c'</sup> forms a bond, a methylene bridge or an ethylene bridge; and

R<sup>4f</sup> and R<sup>4f'</sup> are each independently hydrogen, cyano, hydroxy, amino, H<sub>2</sub>NC(O)-, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, di(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, (C<sub>3</sub>-C<sub>6</sub>)cycloalkylamino-, acylamino-, aryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or either R<sup>4f</sup> or R<sup>4f'</sup> taken together with R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, or R<sup>4c'</sup> forms a bond, a methylene bridge or an ethylene bridge;

provided that when R<sup>4</sup> is a group of Formula (IA), then (a) at least one of R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, R<sup>4c'</sup>, R<sup>4d</sup>, R<sup>4d'</sup>, R<sup>4d''</sup>, R<sup>4e</sup>, R<sup>4e'</sup>, R<sup>4f</sup> and R<sup>4f'</sup> is other than hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl; and (b) Y is not oxygen, sulfur or -NH-, when X and Z are a bond, -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-, and R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4f</sup> and R<sup>4f'</sup> are hydrogen; or

(ii) a group having Formula (IC)



(IC)


where R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl, and R<sup>7</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl-, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl-, (C<sub>1</sub>-C<sub>4</sub>)alkoxy(C<sub>1</sub>-C<sub>4</sub>)alkyl-, (C<sub>1</sub>-C<sub>4</sub>)alkylamino(C<sub>1</sub>-C<sub>4</sub>)alkyl-, di(C<sub>1</sub>-C<sub>4</sub>)alkylamino(C<sub>1</sub>-C<sub>4</sub>)alkyl-, or a partially or fully

saturated 4- to 6-membered heterocyclic ring containing 1 to 2 heteroatoms independently selected from oxygen, sulfur or nitrogen,

or  $R^5$  and  $R^6$  or  $R^5$  and  $R^7$  taken together form a 5- or 6-membered lactone, 4- to 6-membered lactam, or a partially or fully saturated 4- to 6-membered heterocycle, where said 4- to 6-membered heterocycle contains 1 to 2 heteroatoms independently selected from oxygen, sulfur or nitrogen, and where said lactone, said lactam and said heterocycle are optionally substituted;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2(previously presented). The compound of Claim 1 wherein  $R^4$  is a group having Formula (IA)



where,

$R^{4b}$  and  $R^{4b'}$  are each independently hydrogen,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)$ alkyl, acyl,  $(C_1-C_3)$ alkyl-O-C(O)-,  $(C_1-C_4)$ alkyl-NH-C(O)-,  $(C_1-C_4)$ alkyl) $_2$ N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4b}$  or  $R^{4b'}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4p}$  forms a bond, a methylene bridge, or an ethylene bridge;

X is a bond,  $-CH_2CH_2-$  or  $-C(R^{4c})(R^{4c'})-$ , where  $R^{4c}$  is hydrogen, cyano, hydroxy, amino,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, acyloxy, acyl,  $(C_1-C_3)$ alkyl-O-C(O)-,  $(C_1-C_4)$ alkyl-NH-C(O)-,  $(C_1-C_4)$ alkyl) $_2$ N-C(O)-,  $(C_1-C_6)$ alkylamino-,  $((C_1-C_4)$ alkyl) $_2$ amino-,  $(C_3-C_6)$ cycloalkylamino-, acylamino-, aryl $(C_1-C_4)$ alkylamino-, heteroaryl $(C_1-C_4)$ alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully

saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4c}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge, or an ethylene bridge, and

$R^{4c'}$  is hydrogen,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)alkyl$ , acyl,  $(C_1-C_3)alkyl-O-C(O)-$ ,  $(C_1-C_4)alkyl-NH-C(O)-$ ,  $(C_1-C_4)alkyl)_2N-C(O)-$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4c'}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge, or an ethylene bridge;

Y is oxygen, sulfur,  $-C(O)-$ , or  $-C(R^{4d})(R^{4d'})-$ , where  $R^{4d}$  is hydrogen, cyano, hydroxy, amino,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)alkyl$ ,  $(C_1-C_6)alkoxy$ , acyloxy, acyl,  $(C_1-C_3)alkyl-O-C(O)-$ ,  $(C_1-C_4)alkyl-NH-C(O)-$ ,  $(C_1-C_4)alkyl)_2N-C(O)-$ ,  $(C_1-C_6)alkylamino-$ ,  $((C_1-C_4)alkyl)_2amino-$ ,  $(C_3-C_6)cycloalkylamino-$ , acylamino-, aryl $(C_1-C_4)alkylamino-$ , heteroaryl $(C_1-C_4)alkylamino-$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted, and

$R^{4d'}$  is hydrogen,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)alkyl$ , acyl,  $(C_1-C_3)alkyl-O-C(O)-$ ,  $(C_1-C_4)alkyl-NH-C(O)-$ ,  $(C_1-C_4)alkyl)_2N-C(O)-$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4d}$  and  $R^{4d'}$  taken together form a partially or fully saturated 3- to 6-membered heterocyclic ring, a 5- or 6-membered lactone ring, or a 4- to 6-membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, or

Y is  $-NR^{4d''}-$ , where  $R^{4d''}$  is a hydrogen or a chemical moiety selected from the group consisting of  $(C_1-C_6)alkyl$ ,  $(C_3-C_6)cycloalkyl$ ,  $(C_1-C_3)alkylsulfonyl-$ ,  $(C_1-$

C<sub>3</sub>)alkylaminosulfonyl-, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl-, acyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-C(O)-, aryl, and heteroaryl, where said chemical moiety is optionally substituted;

Z is a bond, -CH<sub>2</sub>CH<sub>2</sub>-, or -C(R<sup>4e</sup>)(R<sup>4e'</sup>)-, where R<sup>4e</sup> is hydrogen, cyano, hydroxy, amino, H<sub>2</sub>NC(O)-, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>amino-, (C<sub>3</sub>-C<sub>6</sub>)cycloalkylamino-, acylamino-, aryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or R<sup>4e</sup> taken together with R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, or R<sup>4c'</sup> forms a bond, a methylene bridge, or an ethylene bridge, and

R<sup>4e'</sup> is hydrogen, H<sub>2</sub>NC(O)-, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or R<sup>4e'</sup> taken together with R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, or R<sup>4c'</sup> forms a bond, a methylene bridge, or an ethylene bridge; and

R<sup>4f</sup> and R<sup>4f'</sup> are each independently hydrogen, H<sub>2</sub>NC(O)-, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or R<sup>4f</sup> or R<sup>4f'</sup> taken together with R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, or R<sup>4c'</sup> forms a bond, a methylene bridge, or an ethylene bridge;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

3(original). The compound of Claim of 2 wherein

A and B are each independently a substituted phenyl;

R<sup>4b</sup> is hydrogen, an optionally substituted (C<sub>1</sub>-C<sub>3</sub>)alkyl, or taken together with R<sup>4e</sup>, R<sup>4e'</sup>, R<sup>4f</sup>, or R<sup>4f'</sup> forms a bond, a methylene bridge, or an ethylene bridge;

$R^{4b'}$  is hydrogen, an optionally substituted (C<sub>1</sub>-C<sub>3</sub>)alkyl, or taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge, or an ethylene bridge;

$R^{4f}$  is hydrogen, an optionally substituted (C<sub>1</sub>-C<sub>3</sub>)alkyl, or taken together with  $R^{4b}$ ,  $R^{4b'}$ ,  $R^{4c}$ , or  $R^{4c'}$  forms a bond, a methylene bridge, or an ethylene bridge; and

$R^{4f'}$  is hydrogen, an optionally substituted (C<sub>1</sub>-C<sub>3</sub>)alkyl, or taken together with  $R^{4b}$ ,  $R^{4b'}$ ,  $R^{4c}$ , or  $R^{4c'}$  forms a bond, a methylene bridge, or an ethylene bridge;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

4(previously presented). The compound of Claim 3 wherein

X is  $-C(R^{4c})(R^{4c'})-$ , where  $R^{4c}$  and  $R^{4c'}$  are each independently hydrogen,  $H_2NC(O)-$ , an optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, or ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-,

or either  $R^{4c}$  or  $R^{4c'}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge or an ethylene bridge;

Y is  $-NR^{4d''}$ ,  $R^{4d''}$  is a hydrogen or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>3</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl, acyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-C(O)-, aryl, and heteroaryl, where said chemical moiety is optionally substituted;

Z is  $-C(R^{4e})(R^{4e'})-$ , where  $R^{4e}$  and  $R^{4e'}$  are each independently hydrogen,  $H_2NC(O)-$ , an optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, or ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-,

or either  $R^{4e}$  or  $R^{4e'}$  taken together with  $R^{4b}$ ,  $R^{4b'}$ ,  $R^{4c}$ , or  $R^{4c'}$  forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5(previously presented). The compound of Claim 4 wherein  $R^{4d''}$  is a hydrogen or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>3</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl, acyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-C(O)-, and heteroaryl, where said chemical moiety is optionally substituted;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

6(previously presented). The compound of Claim 5 wherein R<sup>4d</sup> is a hydrogen or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>3</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl, acyl, and (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-C(O)-, where said chemical moiety is optionally substituted with 1-3 fluorines,

or R<sup>4d</sup> is a heteroaryl, where said heteroaryl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkyl, and fluoro-substituted (C<sub>1</sub>-C<sub>3</sub>)alkyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

7(original). The compound of Claim 4, 5 or 6 wherein A and B are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

8(original). The compound of Claim 7 wherein A and B are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, fluoro-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

9(original). The compound of Claim 8 wherein A is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and B is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

10(original). The compound of Claim 9 selected from the group consisting of 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-pyridin-2-ylpiperazin-1-yl)-9H-purine;



9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-pyrimidin-2-ylpiperazin-1-yl)-9H-purine; and

4-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperazine-2-carboxylic acid methylamide;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

11(previously presented). The compound of Claim 3 wherein Y is  $-C(R^{4d})(R^{4d'})-$ , where  $R^{4d}$  is hydrogen, cyano, hydroxy, amino,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, acyloxy, acyl,  $(C_1-C_3)$ alkyl-O-C(O)-,  $(C_1-C_4)$ alkyl-NH-C(O)-,  $(C_1-C_4)$ alkyl<sub>2</sub>N-C(O)-,  $(C_1-C_6)$ alkylamino-,  $((C_1-C_4)$ alkyl)<sub>2</sub>amino-,  $(C_3-C_6)$ cycloalkylamino-, acylamino-, aryl $(C_1-C_4)$ alkylamino-, heteroaryl $(C_1-C_4)$ alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

$R^{4d'}$  is hydrogen,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)$ alkyl, acyl,  $(C_1-C_3)$ alkyl-O-C(O)-,  $(C_1-C_4)$ alkyl-NH-C(O)-,  $(C_1-C_4)$ alkyl<sub>2</sub>N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4d}$  and  $R^{4d'}$  taken together form a partially or fully saturated, 3- to 6-membered heterocyclic ring, a 5- or 6-membered lactone ring, or a 4- to 6-membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

12(original). The compound of Claim 11 wherein

$R^{4b}$ ,  $R^{4b'}$ ,  $R^{4f}$ , and  $R^{4f'}$  are all hydrogen;

$R^{4d}$  is amino,  $(C_1-C_6)$ alkylamino,  $di(C_1-C_4)$ alkylamino,  $(C_3-C_6)$ cycloalkylamino, acylamino, aryl $(C_1-C_4)$ alkylamino-, heteroaryl $(C_1-C_4)$ alkylamino-; and

$R^{4d'}$  is  $(C_1-C_6)$ alkyl,  $H_2NC(O)-$ ,  $(C_1-C_4)$ alkyl-NH-C(O)-, or  $((C_1-C_4)alkyl)_2N-C(O)-$ , or aryl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

13(original). The compound of Claim 12 wherein

X is a bond or  $-C(R^{4c})(R^{4c'})-$ , where  $R^{4c}$  and  $R^{4c'}$  are each hydrogen; and

Z is a bond or  $-C(R^{4e})(R^{4e'})-$ , where  $R^{4e}$  and  $R^{4e'}$  are each hydrogen;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

14(original). The compound of Claim 13 wherein  $R^{4d}$  is amino,  $(C_1-C_6)$ alkylamino,  $di(C_1-C_4)$ alkylamino,  $(C_3-C_6)$ cycloalkylamino; and

$R^{4d'}$  is  $H_2NC(O)-$ ,  $(C_1-C_4)$ alkyl-NH-C(O)-, or  $((C_1-C_4)alkyl)_2N-C(O)-$ ;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

15(original). The compound of Claim 11, 12, 13 or 14 wherein A and B are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo,  $(C_1-C_4)$ alkoxy,  $(C_1-C_4)$ alkyl, halo-substituted  $(C_1-C_4)$ alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

16(original). The compound of Claim 15 wherein A and B are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro,  $(C_1-C_4)$ alkoxy,  $(C_1-C_4)$ alkyl, fluoro-substituted  $(C_1-C_4)$ alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

17(original). The compound of Claim 16 wherein A is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and B is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

18(original). The compound of Claim 17 selected from the group consisting of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-9H-purin-6-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-pyrrolidin-1-yl-piperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide;

4-amino-1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperidine-4-carboxylic acid amide; and

1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-methylaminopiperidine-4-carboxylic acid amide;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

19(original). The compound of Claim 18 selected from the group consisting of

1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-isopropylamino-piperidine-4-carboxylic acid amide;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide;

4-amino-1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperidine-4-carboxylic acid amide; and

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylamino-piperidine-4-carboxylic acid amide;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

20(previously presented). The compound of Claim 11 wherein

$R^{4b}$ ,  $R^{4b'}$ ,  $R^{4f}$ , and  $R^{4f'}$  are all hydrogen;

$R^{4d}$  is hydrogen, hydroxy, amino, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, and di(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, where said chemical moiety is optionally substituted; and

$R^{4d'}$  is hydrogen, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl and heteroaryl, where said chemical moiety is optionally substituted;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

21(original). The compound of Claim 20 wherein

X is -C( $R^{4c}$ )( $R^{4c'}$ )-, where  $R^{4c}$  and  $R^{4c'}$  are each independently hydrogen or an optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, or either  $R^{4c}$  or  $R^{4c'}$  taken together with  $R^{4e}$  or  $R^{4e'}$  forms a bond, a methylene bridge or an ethylene bridge; and

Z is -C( $R^{4e}$ )( $R^{4e'}$ )-, where  $R^{4e}$  and  $R^{4e'}$  are each independently hydrogen or an optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, or either  $R^{4e}$  or  $R^{4e'}$  taken together with  $R^{4c}$  or  $R^{4c'}$  forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

22(previously presented). The compound of Claim 21 wherein

$R^{4c}$  and  $R^{4c'}$  are each hydrogen or either  $R^{4c}$  or  $R^{4c'}$  taken together with  $R^{4e}$  or  $R^{4e'}$  forms a bond;

$R^{4d}$  is hydrogen, hydroxy, amino, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, and di(C<sub>1</sub>-C<sub>4</sub>)alkylamino-;

$R^{4d'}$  is hydrogen, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl and aryl, where said chemical moiety is optionally substituted; and

$R^{4e}$  and  $R^{4e'}$  are hydrogen or either  $R^{4e}$  or  $R^{4e'}$  taken together with  $R^{4c}$  or  $R^{4c'}$  forms a bond;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

23(original). The compound of Claim 20, 21, or 22 wherein A and B are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

24(original). The compound of Claim 23 wherein A and B are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, fluoro-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

25(original). The compound of Claim 24 wherein A is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and B is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

26(original). The compound of Claim 25 selected from the group consisting of 1-{1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-phenylpiperidin-4-yl}-ethanone;

[3-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-3-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-azabicyclo[3.1.0]hex-6-yl]-dimethylamine;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-(4-fluorophenyl)-piperidin-4-ol;

1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-phenylpiperidin-4-ol;

and

4-benzyl-1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperidin-4-ol;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

27(original). The compound of Claim 11 wherein

R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4f</sup>, and R<sup>4f'</sup> are all hydrogen; and

R<sup>4d</sup> and R<sup>4d'</sup> taken together form a partially or fully saturated 3- to 6-membered heterocyclic ring, a 5- or 6-membered lactone ring, or a 4- to 6-membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted and said lactone ring or said lactam ring optionally contains an additional heteroatom selected from oxygen, nitrogen or sulfur;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

28(original). The compound of Claim 27 wherein

X is a bond, -CH<sub>2</sub>CH<sub>2</sub>- or -C(R<sup>4c</sup>)(R<sup>4c'</sup>)-, where R<sup>4c</sup> and R<sup>4c'</sup> are each independently hydrogen or an optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, or either R<sup>4c</sup> or R<sup>4c'</sup> taken together with R<sup>4e</sup> or R<sup>4e'</sup> forms a bond, a methylene bridge or an ethylene bridge; and

Z is a bond, -CH<sub>2</sub>CH<sub>2</sub>- or -C(R<sup>4e</sup>)(R<sup>4e'</sup>)-, where R<sup>4e</sup> and R<sup>4e'</sup> are each independently hydrogen or an optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, or either R<sup>4e</sup> or R<sup>4e'</sup> taken together with R<sup>4c</sup> or R<sup>4c'</sup> forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

29(original). The compound of Claim 27 wherein  $R^{4d}$  and  $R^{4d'}$  taken together form a 5 or 6 membered lactam ring, where said lactam ring is optionally substituted and optionally contains an additional heteroatom selected from nitrogen or oxygen;  
a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

30(original). The compound of Claim 29 wherein  
X is a bond or  $-C(R^{4c})(R^{4c'})-$ , where  $R^{4c}$  and  $R^{4c'}$  are each hydrogen; and  
Z is a bond or  $-C(R^{4e})(R^{4e'})-$ , where  $R^{4e}$  and  $R^{4e'}$  are each hydrogen;  
a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

31(original). The compound of Claim 27, 28, 29 or 30 wherein A and B are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo,  $(C_1-C_4)$ alkoxy,  $(C_1-C_4)$ alkyl, halo-substituted  $(C_1-C_4)$ alkyl, and cyano;  
a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

32(original). The compound of Claim 31 wherein A and B are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro,  $(C_1-C_4)$ alkoxy,  $(C_1-C_4)$ alkyl, fluoro-substituted  $(C_1-C_4)$ alkyl, and cyano;  
a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

33(original). The compound of Claim 32 wherein A is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and B is 4-chlorophenyl or 4-fluorophenyl;  
a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

34(original). The compound of Claim 30 selected from the group consisting of

8-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one;

8-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; and


9-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-methyl-4-oxa-1,9-diazaspiro[5.5]undecan-2-one;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

35(original). The compound of Claim 34 which is 8-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

36(previously presented). The compound of Claim 1 wherein  $R^4$  is a group of Formula (IB)



where  $R^{4a}$  is as defined in Claim 1;

$R^{4b}$  is hydrogen, cyano, hydroxy, amino,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, acyloxy, acyl,  $(C_1-C_3)$ alkyl-O-C(O)-,  $(C_1-C_4)$ alkyl-NH-C(O)-,  $(C_1-C_4)$ alkyl) $_2$ N-C(O)-,  $(C_1-C_6)$ alkylamino-,  $((C_1-C_4)$ alkyl) $_2$ amino-,  $(C_3-C_6)$ cycloalkylamino-, acylamino-, aryl $(C_1-C_4)$ alkylamino-, heteroaryl $(C_1-C_4)$ alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

$R^{4b'}$  is hydrogen,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of  $(C_1-C_6)$ alkyl, acyl,  $(C_1-C_3)$ alkyl-O-C(O)-,  $(C_1-C_4)$ alkyl-NH-C(O)-,  $(C_1-C_4)$ alkyl) $_2$ N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered



heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4b}$  or  $R^{4b'}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge, or an ethylene bridge;

X is a bond,  $-\text{CH}_2\text{CH}_2-$  or  $-\text{C}(\text{R}^{4c})(\text{R}^{4c'})-$ , where  $\text{R}^{4c}$  is hydrogen, cyano, hydroxy, amino,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , acyloxy, acyl,  $(\text{C}_1-\text{C}_3)\text{alkyl-O-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl-NH-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl})_2\text{N-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_6)\text{alkylamino-}$ ,  $((\text{C}_1-\text{C}_4)\text{alkyl})_2\text{amino-}$ ,  $(\text{C}_3-\text{C}_6)\text{cycloalkylamino-}$ , acylamino-, aryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , heteroaryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $\text{R}^{4c}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge, or an ethylene bridge, and

$\text{R}^{4c'}$  is hydrogen,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ , acyl,  $(\text{C}_1-\text{C}_3)\text{alkyl-O-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl-NH-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl})_2\text{N-C}(\text{O})-$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $\text{R}^{4c'}$  taken together with  $R^{4e}$ ,  $R^{4e'}$ ,  $R^{4f}$ , or  $R^{4f'}$  forms a bond, a methylene bridge, or an ethylene bridge;

Y is oxygen, sulfur,  $-\text{C}(\text{O})-$ , or  $-\text{C}(\text{R}^{4d})(\text{R}^{4d'})-$ , where  $\text{R}^{4d}$  is hydrogen, cyano, hydroxy, amino,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , acyloxy, acyl,  $(\text{C}_1-\text{C}_3)\text{alkyl-O-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl-NH-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl})_2\text{N-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_6)\text{alkylamino-}$ ,  $((\text{C}_1-\text{C}_4)\text{alkyl})_2\text{amino-}$ ,  $(\text{C}_3-\text{C}_6)\text{cycloalkylamino-}$ , acylamino-, aryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , heteroaryl $(\text{C}_1-\text{C}_4)\text{alkylamino-}$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted, and

$\text{R}^{4d'}$  is hydrogen,  $\text{H}_2\text{NC}(\text{O})-$ , or a chemical moiety selected from the group consisting of  $(\text{C}_1-\text{C}_6)\text{alkyl}$ , acyl,  $(\text{C}_1-\text{C}_3)\text{alkyl-O-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl-NH-C}(\text{O})-$ ,  $(\text{C}_1-\text{C}_4)\text{alkyl})_2\text{N-C}(\text{O})-$ , aryl, heteroaryl, a partially or fully saturated 3- to 6-membered

heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4d}$  and  $R^{4d'}$  taken together form a partially or fully saturated 3- to 6-membered heterocyclic ring, a 5- or 6-membered lactone ring, or a 4- to 6-membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur;

Y is  $-NR^{4d''}$ -, where  $R^{4d''}$  is a hydrogen or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>3</sub>)alkylsulfonyl-, (C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl-, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl-, acyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-C(O)-, aryl, and heteroaryl, where said chemical moiety is optionally substituted;

Z is a bond,  $-CH_2CH_2-$ , or  $-C(R^{4e})(R^{4e'})-$ , where  $R^{4e}$  is hydrogen, cyano, hydroxy, amino,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>amino-, (C<sub>3</sub>-C<sub>6</sub>)cycloalkylamino-, acylamino-, aryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4e}$  taken together with  $R^{4b}$ ,  $R^{4b'}$ ,  $R^{4c}$ , or  $R^{4c'}$  forms a bond, a methylene bridge, or an ethylene bridge, and

$R^{4e'}$  is hydrogen,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or  $R^{4e'}$  taken together with  $R^{4b}$ ,  $R^{4b'}$ ,  $R^{4c}$ , or  $R^{4c'}$  forms a bond, a methylene bridge, or an ethylene bridge;

$R^{4f}$  is hydrogen, cyano, hydroxy, amino,  $H_2NC(O)-$ , or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyloxy, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino-, ((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>amino-, (C<sub>3</sub>-C<sub>6</sub>)cycloalkylamino-, acylamino-, aryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-,

heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkylamino-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted; and

R<sup>4f</sup> is hydrogen, H<sub>2</sub>NC(O)-, or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, acyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl-O-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl-NH-C(O)-, (C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3- to 6-membered heterocycle, and a partially or fully saturated 3- to 8-membered carbocyclic ring, where said chemical moiety is optionally substituted,

or R<sup>4f</sup> or R<sup>4f</sup> taken together with R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4c</sup>, or R<sup>4c'</sup> forms a bond, a methylene bridge, or an ethylene bridge;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

37(original). The compound of Claim 36 wherein

A and B are each independently a substituted phenyl;

R<sup>4a</sup>, R<sup>4b</sup>, R<sup>4b'</sup>, R<sup>4f</sup> and R<sup>4f</sup> are each hydrogen;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

38(previously presented). The compound of Claim 37 wherein

X is a bond, -CH<sub>2</sub>CH<sub>2</sub>- or -C(R<sup>4c</sup>)(R<sup>4c'</sup>)-, where R<sup>4c</sup> and R<sup>4c'</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

Y is -NR<sup>4d''</sup>-, where R<sup>4d''</sup> is hydrogen or a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>3</sub>)alkylsulfonyl-, (C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl-, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminosulfonyl-, acyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-C(O)-, aryl, and heteroaryl, where said chemical moiety is optionally substituted;

Z is a bond, -CH<sub>2</sub>CH<sub>2</sub>- or -C(R<sup>4c</sup>)(R<sup>4c'</sup>)-, where R<sup>4c</sup> and R<sup>4c'</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

39(original). The compound of Claim 37 or 38 wherein A and B are each independently a phenyl substituted with 1 to 3 substituents independently selected from

the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

40(original). The compound of Claim 39 wherein A and B are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, fluoro-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

41(original). The compound of Claim 40 wherein A is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and B is 4-chlorophenyl or 4-fluorophenyl;


a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

42(original). The compound of Claim 41 selected from the group consisting of 6-(1-benzylpyrrolidin-3-yloxy)-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine; and

9-(4-chlorophenyl)-6-(1-cyclohexylazetidin-3-yloxy)-8-(2,4-dichlorophenyl)-9H-purine;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

43(previously presented). The compound of Claim 1 wherein R<sup>4</sup> is a group having Formula (IC)



(IC)

where R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl, and R<sup>7</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl-, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl-, (C<sub>1</sub>-C<sub>4</sub>)alkoxy(C<sub>1</sub>-C<sub>4</sub>)alkyl-, (C<sub>1</sub>-

C<sub>4</sub>alkylamino(C<sub>1</sub>-C<sub>4</sub>)alkyl-, di(C<sub>1</sub>-C<sub>4</sub>)alkylamino(C<sub>1</sub>-C<sub>4</sub>)alkyl-, or a partially or fully saturated 4- to 6-membered heterocyclic ring containing 1 to 2 heteroatoms independently selected from oxygen, sulfur or nitrogen, or

R<sup>5</sup> and R<sup>6</sup>, or R<sup>5</sup> and R<sup>7</sup> taken together form a 5- or 6-membered lactone, 4- to 6-membered lactam, or a partially or fully saturated 4- to 6-membered heterocycle, where said 4- to 6-membered heterocycle contains 1 to 2 heteroatoms independently selected from oxygen, sulfur or nitrogen, and where said lactone, said lactam and said heterocycle are optionally substituted;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

44(original). The compound of Claim 43 wherein A and B are each independently a substituted phenyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

45(original). The compound of Claim 44 wherein R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl, and R<sup>7</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

46(original). The compound of Claim 44 or 45 wherein A and B are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

47(original). The compound of Claim 46 wherein A and B are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, fluoro-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

48(original). The compound of Claim 47 wherein A is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and B is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

49(original). The compound of Claim 48 selected from the group consisting of 6-tert-butoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine; and 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-isopropoxy-9H-purine;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

50(original). A pharmaceutical composition comprising (1) a compound of Claim 1, a prodrug of said compound, a pharmaceutically acceptable salt of said compound or said prodrug, or a solvate or hydrate of said compound, said prodrug, or said salt; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

51(currently amended). The composition of Claim 50 further comprising at least one additional pharmaceutical agent, wherein said additional pharmaceutical agent is a nicotine receptor partial agonist, an opioid antagonist, a dopaminergic agent, an attention deficit disorder agent, or an anti-obesity agent.

52(cancelled).

53(currently amended). The composition of ~~Claim 52~~ Claim 51 wherein said anti-obesity agent is selected from the group consisting of an apo-B/MTP inhibitor, an 11 $\beta$ -hydroxy steroid dehydrogenase-1 inhibitor, peptide YY<sub>3-36</sub>, a MCR-4 agonist, a CCK-A agonist, a monoamine reuptake inhibitor, a sympathomimetic agent, a  $\beta_3$  adrenergic receptor agonist, a dopamine agonist, a melanocyte-stimulating hormone receptor analog, a 5-HT<sub>2c</sub> receptor agonist, a melanin concentrating hormone antagonist, leptin, a leptin analog, a leptin receptor agonist, a galanin receptor antagonist, a lipase inhibitor, a bombesin receptor agonist, a neuropeptide-Y receptor antagonist, a thyromimetic agent, dehydroepiandrosterone or analog thereof, a

glucocorticoid receptor antagonist, an orexin receptor antagonist, a glucagon-like peptide-1 receptor agonist, a ciliary neurotrophic factor, a human agouti-related protein antagonist, a ghrelin receptor antagonist, a histamine 3 receptor antagonist or inverse agonist, and a neuromedin U receptor agonist.

Claims 54-76(cancelled).


77(previously presented). The composition of Claim 51 wherein said additional pharmaceutical agent is an opioid antagonist.

78(previously presented). A compound which is 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;  
a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

79(previously presented). The compound of Claim 78 wherein said compound is a mesylate, besylate or hydrochloride salt; or a solvate or hydrate of said salt.

80(previously presented). The compound of Claim 79 which is a hydrochloride salt or hydrate of said hydrochloride salt.

81(previously presented). A compound having the following structure



82(new). The composition of Claim 50 wherein said compound of Claim 1 is 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;  
a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

83(new). The composition of Claim 51 wherein said compound of Claim 1 is 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

84(new). The composition of Claim 83 wherein said additional pharmaceutical agent is an opioid antagonist or an anti-obesity agent.